Pharma Profits on Slippery Slope?

Some fourth quarter data are in from the pharmaceutical industry and, on the surface, it looks good for profits: Pfizer said it earned $4.39 billion, or 58 cents a share, in the...

Drug Prices/Declining Profits Top Issues for 2005

According to results of the recent Pharma Marketing News 2005 HOT ISSUE survey, drug prices, declining profits, and dwindling pipeline of new drugs are the top issues that will have the...

How the FDA Can Fix DTC

According to today's Financial Times (FT), executives from UK pharma companies GlaxoSmithKline and AstraZeneca told a UK parliamentary committee they did not believe it was appropriate (my emphasis) for Britain to...

Does the FDA Need to be Overhauled?

The Vioxx withdrawal put the Food and Drug Administration (FDA) under the spotlight. There were allegations that the FDA was in cahoots with Merck in keeping Vioxx problems under wraps (see,...

Drug Prices, Declining Profits Top Pharma Concern

The Pharma Marketing News 2005 HOT ISSUE Survey reveals some insight into the issues of most concern to pharmaceutical marketers in 2005. At the top of the list are drug prices...

ED Drug Sales Limp

The Wall Street Journal reports today that all is not well in the impotence-drug market. "The growth since the competition came to the market has been modest and below expectations for the...

The End of DTC as We Know It

During the presidential election campaign of 2004, several pharma industry trade publications suggested that if Kerry/Edwards won the election, DTC (Direct to Consumer) ads for drugs would be banned. To be...

Canada: Mad Cows Yes, Drugs No!

Canadian health officials are drafting a proposal that could halt Internet sales of prescription drugs to U.S. consumers, which could "essentially kill" a $700 million industry, the AP/Washington Post reports (see...

The Pharma Industry Has Issues in 2005

In his excellent article, What Merck has to do to remain an independent drug maker, business writer Donald Johnson lists the following 10 scientific, political, financial, and marketing issues facing Merck...

Who Should Pay for Merck’s Obstructionism?

When public corporations break the law or act deceptively, it is often the small investor who pays the price. This was clearly evident in the case of Enron. In that case,...

Pharma Marketing News, Blog Posts, Events, Podcasts

- Advertisement -